ArticleStem cell reviews and reports2011
Claudins and cancer stem cells.
Article in Stem cell reviews and reports, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Genome-wide CRISPR screening identifiesOncology letters · 2026Article
- MicroRNA-1303 in cancer pathogenesis and therapy: clinical implications for biomarker development and targeted treatment strategies.Cancer cell international · 2025Review
- Correlation of CLDN18.2 and Tumor Microenvironment in Gastric Cancer: A Systematic Review.Cancers · 2025Review
- Article
- Exploring Potential Biomarkers in Oesophageal Cancer: A Comprehensive Analysis.International journal of molecular sciences · 2024Review
- Review
- Efficacy and safety of zolbetuximab for first-line treatment of advanced Claudin 18. 2-positive gastric or gastro-esophageal junction adenocarcinoma: a systematic review and meta-analysis of randomized controlled trials.Frontiers in oncology · 2023Article
- Claudin-7 deficiency promotes stemness properties in colorectal cancer through Sox9-mediated Wnt/β-catenin signalling.Journal of translational medicine · 2021Article
- Claudin 18.2 expression in various tumor types and its role as a potential target in advanced gastric cancer.Translational cancer research · 2020Article
- Claudin-1, A Double-Edged Sword in Cancer.International journal of molecular sciences · 2020Review
- DNA methylation maintains the CLDN1-EPHB6-SLUG axis to enhance chemotherapeutic efficacy and inhibit lung cancer progression.Theranostics · 2020Article
- Targeting claudin-3 suppresses stem cell-like phenotype in nonsquamous non-small-cell lung carcinoma.Lung cancer management · 2019Article
- Expression of Tight Junction Components in Hepatocyte-Like Cells Differentiated from Human Embryonic Stem Cells.Pathology oncology research : POR · 2015Article
- miR-1303 targets claudin-18 gene to modulate proliferation and invasion of gastric cancer cells.Digestive diseases and sciences · 2014Article
- Emerging roles of claudins in human cancer.International journal of molecular sciences · 2013Review
- Down-regulation of claudin-18 is associated with the proliferative and invasive potential of gastric cancer at the invasive front.PloS one · 2013Article
- Methods to examine tight junction physiology in cancer stem cells: TEER, paracellular permeability, and dilution potential measurements.Stem cell reviews and reports · 2012Article
- The malignant social network: cell-cell adhesion and communication in cancer stem cells.Cell adhesion & migrationReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
Abstract
It is now believed that most epithelial tumors are maintained by a subpopulation of cells called cancer stem cells (CSCs) or tumor initiating cells (TICs) with stem cell-like properties, including self-renewal and multilineage differentiation capacity. Recently new insights into this population have emerged in certain epithelial tumor types, including their Claudin(low) phenotype and its importance to the epithelial-mesenchymal transition (EMT) process. Taken together, CSCs, EMT and Claudins appear to constitute an axis-of-evil in cancer, for which better understanding may lead to new therapeutic platforms.
Indexed as
Identifiers
21526417What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.